Creative Medical Technology (NASDAQ:CELZ) Shares Up 3% – Still a Buy?

Shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) rose 3% during mid-day trading on Monday . The company traded as high as $2.11 and last traded at $2.08. Approximately 25,616 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 145,977 shares. The stock had previously closed at $2.02.

Wall Street Analyst Weigh In

CELZ has been the subject of several analyst reports. Wall Street Zen cut Creative Medical Technology from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Creative Medical Technology in a report on Monday, December 29th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Creative Medical Technology has an average rating of “Reduce”.

Creative Medical Technology Stock Up 3.0%

The business’s fifty day moving average is $2.16 and its two-hundred day moving average is $2.89. The stock has a market cap of $5.37 million, a price-to-earnings ratio of -0.71 and a beta of 2.08.

Creative Medical Technology (NASDAQ:CELZ) last posted its quarterly earnings results on Friday, November 7th. The company reported ($0.48) EPS for the quarter, hitting the consensus estimate of ($0.48). As a group, sell-side analysts expect that Creative Medical Technology Holdings, Inc. will post -3.19 earnings per share for the current year.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.